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Abstract
Aim—Skin conductance (SC) provides an objective measure of autonomic system regulation
through sympathetic-mediated filling of sweat glands. This study aimed to test the utility of SC to
detect sympathetic activation in neonatal abstinence syndrome (NAS).
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Methods—14 term (mean, SE: 38.8 ± 0.35 weeks gestational age) neonates with chronic prenatal
opiate exposure were enrolled. SC (peaks/sec and mean of peaks) were measured at baseline,
during heel lance/squeeze (HLS) and recovery from HLS at 24-48 (mean 38) hours of life prior to
treatment for NAS. Blinded coders with established reliability assessed neonates using the
Modified Finnegan Neonatal Scoring System (MFNSS). Non-parametric tests were used to
determine group differences, phase differences from baseline to HLS and HLS to recovery, and
associations between MFNSS and SC measures.
Results—Neonates that would later require morphine treatment for NAS (n = 6) had higher
baseline SC mean of peaks than those that did not require treatment (n = 8) (P<0.05). Moreover,
there were unique phase differences between groups and SC positively correlated with MFNSS
(P< 0.05).
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Conclusion—SC provides early identification of NAS severity. However, a larger sample is
needed to determine sensitivity and specificity of SC for early identification of NAS and treatment
effectiveness.
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INTRODUCTION
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Opioid use in pregnancy is an important public health issue. Both prescribed and illicit
opiate use in pregnancy is on the increase (1). The 2010 National Survey on Drug Use and
Health reported that an estimated 4.4% of pregnant women admitted to illicit drug use in the
past 30 days(2). Neonates born to chronic opioid users are at risk for developing Neonatal
Abstinence Syndrome (NAS), a constellation of acute manifestations of opioid withdrawal
which presents early in the postnatal period. The epidemic is sizeable such that by 2009, one
infant per hour was born with NAS in the United States (3, 4). The use of prescription opiate
use amongst pregnant women is a growing concern, with increased incidence of NAS
symptoms and low birth weight in exposed infants (5). Opioids act by inhibiting the release
of norepinephrine at synaptic terminals. A sudden discontinuation of exogenous opiates
results in higher levels of norepinephrine, characterized by central nervous system
irritability and gastrointestinal dysfunction (6). NAS clinical manifestations commonly
include irritability, tremors, seizures, sweating, high-pitched cry, temperature instability,
tachypnea, uncoordinated suck/swallow reflexes, feeding difficulties, vomiting and diarrhea
(6). The onset and severity of these symptoms can vary depending on the type of opioid the
infant was exposed to in utero. According to the Center for Substance Abuse and Treatment,
infants exposed to methadone may exhibit withdrawal symptoms anytime in the first 2
weeks of life, but usually do so within 72 hours of birth, with symptoms lasting days to
weeks, whereas infants exposed to buprenorphine develop symptoms within 12–48 hours of
birth that peak at 72–96 hours and resolve by 7 days (7). The consequences of acute opioid
withdrawal in neonates may be severe, resulting in significant morbidity and even mortality
for some. Furthermore, those infants afflicted with NAS remain at risk for long-term adverse
neurobehavioral outcomes (8, 9).
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Early diagnosis and treatment of NAS is critical for promoting the best outcomes for these
infants. The Finnegan Scoring System remains the most commonly used tool for the
diagnosis of NAS, though it is known to be quite subjective (10, 11). Therefore the need for
an objective measure in the assessment NAS is underscored.

Author Manuscript

Skin conductance (SC) provides real time, continuous measurement of sympathetic nervous
system (SNS) activity that has potential for use in NAS diagnosis and monitoring. SC
reflects bursts of SNS activity through detection of palmar and plantar sweating. Sweat
release is controlled by the cholinergic sympathetic nervous system, as well as increased
catecholamine response following a stressful condition (12).This is particularly increased in
the palms and soles, where the stratum corneum, epidermis, and eccrine sweat glands are
dense. With sympathetic activation, there are quantifiable increases in the number and
amplitude of electrodermal or skin conductance responses. The use of SC has been well
documented in term and preterm infants with conditions associated with pain, stress, and
arousal (12-15). SC also has been demonstrated to be a better measure of SNS activation
than heart rate or blood pressure, because it is not affected by hemodynamic variability (16).
However, what is unknown is the extent to which SC provides information on SNS
activation associated with neonatal opiate withdrawal. The primary aim of this study was to
test the utility of skin conductance (SC) to detect sympathetic activation in neonatal
abstinence syndrome (NAS). We hypothesized that those infants with high skin conductance
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levels at baseline and with a painful stimulus such as a heel lance would also have high
scores on the Modified Finnegan Neonatal Scoring System (MFNSS) and require
pharmacological intervention.

METHODS
Ethics
The study protocol was reviewed for ethical and regulatory compliance and approved by the
institutional review board at the study site. Informed, written parental consent was obtained
for each study subject.
Participants and setting

Author Manuscript

This study was an observational, feasibility study with each NAS infant serving as her/his
own control. The setting was a level IV tertiary referral neonatal intensive care unit (NICU)
and a newborn nursery, located within an academic medical center in south central
Pennsylvania, USA. Fourteen term NAS infants, post-menstrual age of 37weeks to 41
weeks, with hemodynamic and cardio-pulmonary stability after birth, were enrolled during
November 2012 to January 2014. Mothers of study subjects were identified by the
perinatologist providing care to be opiate dependent, with chronic use during pregnancy
(defined as greater than one intrapartum month), but without other significant co-morbidities
(i.e. diabetes, pre-eclampsia). Exclusion criteria were: infants requiring mechanical
ventilation, major congenital anomalies, hypoglycemia, perinatal exposure to magnesium
sulphate, and maternal poly drug use.
Procedure
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A review of the electronic medical record (EMR) was performed for detailed maternal
medical history and neonatal demographics including: Apgar scores, exposure to magnesium
sulphate, anesthetic agents, and NAS symptomatology and treatment course. Following
birth, all study infants were admitted to the newborn nursery to room-in with their mothers,
per standard clinical practice. Prenatal exposure to opiates was confirmed by positive
toxicology of infants’ meconium.
The standard duration for observation and monitoring of NAS, using the Modified Finnegan
Neonatal Scoring System (MFNSS) was five days. Infants with scores consistently low on
MFNSS (below 8) were discharged after five days of observation, while the infants with
three consecutive scores above 8, or two scores averaging more than 8, were admitted to the
NICU for further assessment and treatment.
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The evaluation of infant response to noxious stimuli was done by observing the response to
blood sampling (heel lance/squeeze) performed as part of the state mandatory newborn
metabolic screen done at 24-48 hours of age. This was an observation of routine care, thus
infants were not subjected to any painful stimulus as part of the research. Study infants were
given standard routine comfort care prior to and during the blood sampling , which included
use of non-nutritive sucking, facilitating self-consoling supportive measures (hands to face,
bracing of extremities), and providing tucked and flexed positioning with a snug wrap. Heel
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lance was performed using a standard lancet, by an experienced nurse after 10 minutes of
baseline skin conductance (SC) recording. SC measurement continued during the heel lance
and squeezing for blood collection, and for additional 10 minutes following completion of
blood collection. The heel lance was performed preferentially on the opposite foot, to avoid
artifact movement to the SC electrodes. During the baseline phase there was no direct
stimulation (i.e. handling or care). The stimulus phase, on the other hand, consisted of heel
warming, skin prep, and the pain phase beginning with heel-lance through termination of
heel squeeze during which the infants’ responses were measured. The recovery phase was
the 10-minute period following heel-lance/squeeze. SC measures were obtained
continuously during the 30 minute observation period, and later analyzed off-line in
baseline, stimulus, and recovery epochs. Figure 1 depicts a sample registration of SC.
Skin conductance apparatus and software
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Skin conductance (SC) activity was measured using the Med-Storm TM device (MedStorm,
Oslo, Norway). The electrical conductance measured by low frequency indicates the ionic
conduction across the stratum corneum of the skin, determined by sweat duct filling (17). To
measure SC activity, three surface electrodes (Conmed ® Corporation, Utica NY, USA)
were applied to the infants’ foot as directed by the manufacturer (18). The electrode system
consists of a measuring electrode, a counter current electrode, and a reference voltage
electrode, to ensure a continuous applied voltage across the stratum corneum beneath the
measuring electrode, as previously described (18-21).

Author Manuscript

The observation/measurement session was standardized to time of day (afternoons, between
12-4pm) and was done after nursing care and post-feeding, in a quiet area with low light and
ambient temperature, to control for extraneous factors known to impact autonomic system
measurement (i.e. circadian fluctuations, feeding and handling cycles) (13, 22). In addition,
we ensured that no painful procedure, such as circumcision or phlebotomy, occurred on the
day that we obtained SC measures. Skin conductance data were analyzed offline, using a
software package provided by the manufacturer (Med Storm Innovation, Oslo Norway). SC
measures included the number of electrodermal responses (EDRs) over time, expressed as
peaks/sec, the average amplitude of the response, expressed as mean of peaks (μsiemens),
and the background, or unstimulated basal level (μsiemens). While the basal activity could
be dominated not by sympathetic activation per se but by a general restlessness, peaks per
second and mean amplitude of peaks represent the strength and sustainability of each sweat
gland burst and thus are most representative of sympathetic arousal. In addition, Storm has
shown that by processing this signal with filtering both ‘noise’ and potential artifacts can be
minimized (14).
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Inter-observer reliability for Modified Neonatal Finnegan Scoring System
Nursing education related to the assessment and scoring of newborns experiencing NAS is
included in the orientation for new nurses. Depending on prior experience, nurses hired for
the well-baby nursery (WBN) and the neonatal intensive care unit (NICU) receive additional
didactic training as self-study or classroom format. The training content is based upon the
Gateway Health Plan DVD, Neonatal Abstinence Syndrome: Assessing the Infant, available
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from: https://www.gatewayhealthplan.com/sites/default/files/documents/
PAMA_neonatal.pdf
For this study, eight nurses with expertise in the care of NAS infants were identified. These
nurses completed an additional independent study of Assessing Signs & Symptoms of
Neonatal Abstinence Using the Finnegan Scoring Tool: An Inter-Observer Reliability
Program© http://www.neoadvances.com/ . The program included a review of scoring
criteria and an assessment of an infant case scenario, followed by a comparison of the
participant’s MFNSS score with that of the expert author. Successful completion of the
program required a minimum 90% agreement with the author. Approximately 6 months after
the initial inter-observer reliability assessment, a second assessment was completed to
ensure ongoing inter-rater agreement >85% as has been previously described (23).
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Statistical analysis
SPSS (IBM version 21, Chicago, Illinois) was used for data entry and analyses. MannWhitney U (non-parametric test) was used to compare continuous variables between treated
and non-treated groups, while Spearman’s correlation coefficients were used to test the
relationships between the Finnegan scores and the SC measures. For within group
comparisons, Wilcoxon Signed Rank tests were used to test phase differences in SC
response at baseline (pre heel lance/squeeze) with pain phase (heel lance/squeeze), and pain
phase with recovery phase (post-heel lance/squeeze). A value of P<0.05 was used for all
tests of significance.

RESULTS
Author Manuscript

Demographic information
Fourteen term infants that met the eligibility criteria for the study were enrolled. The mean ±
SE gestation for infants was 38.8 ±0.35weeks; birth weight was 2850.8±120 grams; and
11(78.6%) were delivered vaginally. None of the study infants was depressed at birth; their
median 5-minute Apgar score was 9 (7-9). None of those enrolled required pharmacologic
treatment for NAS (MFNSS scores were below 8) at the time of the baseline SC
measurements. Six (43%) of the infants studied required subsequent treatment for NAS with
morphine by 72 hours of life. Seventy percent of subjects’ mothers were identified by the
maternal and fetal medicine (MFM) team and maintained on the methadone program. Other
opiate use (i.e. morphine, buprenorphine and oxycodone) in mothers accounted for 30% of
substance use. All study mothers reported to continue cigarette smoking during this
pregnancy. Infant and maternal characteristics are presented in Table 1.
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Descriptive results
The measurement session lasted mean ±SE duration of 30.1 ± 1.1 minutes and occurred
between 24-48 hours of life (mean 38hrs of life). MFNSS done by nurse coders within 1-2
hours of the SC measurement was median (IQR) of 5 (4-10) for the full sample and 10
(8-12) and 4 (3-5) for treatment and non-treatment groups respectively. Skin conductance
obtained at baseline (pre-heel lance/squeeze) for the full sample was basal of 12.7 ±11.5
μsiemens, peaks/sec of 0.22 ± 0.3, and mean of peaks of 0.07 ±0.1 μsiemens. There was a
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marked difference between groups at baseline such that those infants with 3-fold higher
values of skin conductance measures across all three parameters (basal, peaks/sec, and mean
of peaks) later required pharmacologic treatment for NAS.
Between and within group differences
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Both gestational age (GA) and postnatal age in hours at the time of measurement were
similar between groups. Infants in the group requiring later treatment with morphine by 72
hours of life had higher birthweights; however, none of the study infants were large for
gestational age at birth (Table 2). The results of a two-group comparison indicated that
infants with higher basal skin conductance levels at baseline (pre-heel lance/squeeze) and
higher SC mean of peaks at both baseline and recovery (post-heel lance/squeeze), later
required treatment with morphine by 72 hours of life (Table 2). There were no SC
differences between groups during the pain phase (heel lance/squeeze). However, for the
within group comparisons there were significantly higher phase differences in peaks/sec
from baseline to pain phase, and pain phase to recovery in the non-treatment group; with P
values of 0.01 and 0.03 by Wilcoxon Signed Rank tests, respectively. Conversely, those
infants that would later require treatment for NAS by 72 hours of life had a significant phase
difference in peaks/sec from pain phase to recovery of P = 0.04.
Correlations
In the full sample of infants (N=14), the baseline (pre-heel lance/squeeze) SC mean of peaks
showed a direct positive correlation with MFNSS, with Spearman’s correlation coefficient
of 0.65, P=0.01(Figure 2). Basal SC also was directly correlated with MFNSS, with
Spearman’s correlation coefficient of 0.58, P=0.03. In contrast, peaks/sec did not correlate
with MFNSS.
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DISCUSSION
To our knowledge, there are no published studies in NAS infants that have examined
infants’ sympathetic arousal to noxious stimuli using skin conductance. The results of the
present study revealed that infants that had higher SC mean of peaks during both baseline
(pre-pain) and recovery (post-pain) phases at less than 48hrs went on to require
pharmacologic treatment with morphine by 72 hours of age. The height of mean peak
amplitude of SC, strength of the sweat gland burst, represents higher sympathetic activation
in these infants.

Author Manuscript

A second key finding in this investigation, is that there were clear differences in pain
responses (during heel lance/squeeze) when comparing the group of infants that would not
require pharmacologic treatment for opiate withdrawal as opposed to those infants that
needed morphine treatment for NAS by 72 hours. Those infants that would not require later
pharmacotherapy for NAS had significant increases in SC responses (peaks/sec and mean of
peaks) during both the pre-pain to pain phase, and the pain to recovery phase, showing an
expected sympathetic response to the pain stimulus of heel lance/squeeze for blood
sampling. In contrast, those infants that would later require pharmacotherapy for NAS by 72
hours had markedly higher baseline (pre-pain) peaks/sec than those that did not require
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subsequent treatment, and in this group there was only a single between phase differences in
peaks/sec from the pain to recovery phase. We speculate that fewer phase differences in the
treatment group were secondary to an already high sympathetic arousal phenomenon at
baseline (pre-pain stimulus), or a “ceiling effect”, such that, even with a painful stimulus no
further arousal occurred.

Author Manuscript

Our findings are consistent with other studies which have shown mean of peaks and
peaks/sec increase significantly with stimuli such as heel lance, noise, and other stimuli (12,
13, 18, 24). Dalal et al (2013) reported a similar finding when SC was applied in postoperative pediatric (6-12 months of age) patients recovering from anesthesia. In this study,
the mean of peaks and basal levels were more sensitive measures of autonomic arousal than
peaks/sec in the post-operative period in pediatric patients (25). They analyzed acute
behavioral pain scores and SC measures, finding that peak amplitude of SC served as the
best indicator of significant pain in a sample of older infants. In 2000, Storm found SC
amplitude (peaks) and number of waves (peaks/s) increased in response to heel lance, and
returned to pre-heel lance levels in preterm infants >29 weeks gestational age (14). In a
recent study of preterm infants 22-27 weeks GA, investigators found the combination of
both heel lance and heel squeeze produced significant rises in SC peaks/s (26). Gladman et
al. examined healthy term and post-term infants’ baseline and SC responses to heel lance of
varied postmenstrual ages. In the two subgroups of infants 36-39 weeks and 40-43 weeks
GA, investigators found a sharp rise from baseline SC to heel lance for each of the groups at
30% and 95% respectively. While the gestational age of infants in this study was similar to
the infants in our study, these were healthy infants without known exposure to opiates (19) .
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In our study, we noted variations in the SC measures between patients. This suggests a
within-person variability of response to stimuli; this in part may relate to individual variation
in response to environmental challenge (12, 27). It is notable; however, that the infants that
would require pharmacologic treatment for withdrawal within 24 hours of our observation,
had significantly higher baseline (pre-pain phase) mean of peak SC values, and persistently
elevated mean of peak SC levels in recovery (post-pain phase). In contrast, those infants that
did not require later pharmacologic treatment had peak SC values which increased during
pain phase and returned to baseline during the recovery phase. The findings of this study
also indicate direct positive correlation between the mean of peaks SC during the pre-pain
phase with pre-stimulation Finnegan scores.
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The strengths of this study are its prospective nature and application to a population with
well described pathophysiology and relative control of environmental and circadian
influences known to impact SC measurement, such as time of day, infant’s behavioral state,
handling, noise, temperature, ambient light and other noxious influences. We studied only
opiate exposed infants with similar maternal/infant characteristics and excluded poly-drug
exposed infants. Our approach to design and analysis included not only group differences,
but also within group patterns of response where we identified unique phase differences
among groups. This study used a standardized approach to obtaining both biological and
behavioral measures of response for each study subject. Moreover, the abstinence scoring
with MFNSS was done with pre-established inter-rater reliable nurse coders who were
blinded to study aims and SC results.
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The major limitation of this study was our small sample size. However, we found
statistically significant between group and within group differences in skin conductance.
Observing serial measures of SC responses to daily care (i.e. sound and tactile stimuli) may
have proven useful in characterizing non-painful sympathetic arousal (i.e. responses to care,
handling) in this sample of infants. Including a comparison group of healthy term infants not
exposed to opiates also may have proven useful. These approaches were considered but not
undertaken in this small scale feasibility study. Time constraints related to additional
assurances that would be required by the IRB to obtain parental authorization for screening
infants for opiates, not part of standard care, the costs that would be incurred for the
screening, and the sensitive nature of disclosure of the information influenced our decision
to not study a “control” group of infants in this pilot study.

CONCLUSION
Author Manuscript
Author Manuscript

Skin conductance measures were noted to be higher at 24-48 hours of life (mean age of
38hours) at baseline (pre-pain) and recovery (post-pain) in neonates that subsequently
required morphine treatment by 72 hours of life for NAS, in support of our hypothesis. The
SC measures were highly correlated with the MFNSS scores at 24-48hours of life. This
finding has relevance as neonates with higher MFNSS scores typically require
pharmacological therapy. Suggesting, skin conductance may be useful as an important early
objective adjunct to MFNSS for predicting which infants will require later pharmacologic
treatment. Skin conductance may be of particular importance not only in the early
identification of NAS severity, but also in later therapeutic monitoring of NAS treatment.
Further applications of these findings hold promise for the development of an early risk
assessment to identify which neonates may require an extended period of observation and
treatment for the symptoms of withdrawal.
In summary, we suggest that SC can be used effectively with MFNSS as an adjunct in the
assessment of symptoms in NAS. The non-invasive nature of SC measurement, as well as its
portability makes it an attractive tool that may permit continuous real-time monitoring of
sympathetic arousal as seen with NAS. However, further study is required in a larger sample
to determine the sensitivity and specificity of SC for detection of sympathetic arousal by
NAS severity before it can be recommended for clinical application to this population and
setting.
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List of Abbreviations
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NAS

Neonatal Abstinence Syndrome

MFNSS

Modified Finnegan Neonatal Scoring System

SC

Skin Conductance

GA

Gestational Age

BW

Birth Weight

HLS

Heel Lance/Squeeze

WBN

Well Baby Nursery

NICU

Neonatal Intensive Care Unit

MFM

Maternal Fetal Medicine

SE

Standard Error

EMR

Electronic Medical Record

IQR

Inter Quartile Range

EDR

Electrodermal Response (Peaks/s)
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Key Notes
•

Sympathetic-mediated sweat gland filling from emotional distress or pain of
heel-lance/squeeze was measured non-invasively via surface electrodes and
recorded electronically.

•

Skin conductance at baseline and recovery detected higher levels of sympathetic
activation prior to the need for pharmacotherapy for neonatal abstinence
syndrome (NAS).

•

These preliminary findings will inform future investigations to evaluate the
sensitivity and specificity of skin conductance as a test of NAS severity and
treatment effectiveness.
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Figure 1.
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Representative subject from NAS treatment group showing continuous SC data measured
around blood sampling done prior to the need for pharmacologic intervention for NAS. Ten
minutes of baseline data were obtained prior to the blood sampling, next, during blood
sampling showing noxious effects of both lance and heel squeezing, and during the 10
minutes of recovery (post-sampling). Each waveform peak (or electrodermal responseEDR) is noted by a red dot. The frequency of peaks divided by the total time of the epoch in
seconds is EDR/sec or peaks/sec. The mean height of the peaks is noted as mean of peaks.
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Figure 2.

Author Manuscript

Correlation between skin conductance mean of peaks (μS) from the pre-heel lance phase and
the modified Finnegan Neonatal Scoring System for infants prior to the initiation of
pharmacologic intervention (treatment group vs non-treatment group, represents those
requiring later treatment at 72hrs vs those not requiring treatment ). The Spearman’s (rs)
correlation coefficient is 0.65 (P= 0.01).
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Infant and maternal characteristics of the 14 subjects
Infant Characteristics

mean ± SE, n, %
median (IQR)

Gestational age at birth, wks

38.8 ± 0.35

Birth weight, g

2850 ± 120

Gender
Female

5, 36

Male

9, 64

5-min Apgar Score

9 (7-9)

Mode of Delivery
Vaginal Delivery

11, 79

C-section

3, 21

Author Manuscript

Treated for NAS
Yes

6, 43

No

8, 57

Maternal Characteristics

mean ± SE, n, %

Age, yrs

25 ± 1.14

Level of Education
High School

8, 57

College

6, 43

Prenatal Care
Yes

14, 100

Substance Use in Pregnancy
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Methadone

10,70

Other Opiates

4, 30

Cigarette Smoking during index pregnancy

14,100
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Between group comparisons of infants’ characteristics and skin conductance measures
Non-treated infants
mean± (SE)
n=8

Treated infants
mean± (SE)
n=6

Pvalue

GA-weeks

38.3 (0.41)

39.5 (0.51)

0.949

Age in hours at time of SC

38 (3.16)

35 (3.40)

0.347

BW-grams

2665 (98.8)

3098 (219.5)

0.025

Mean of Peaks, μsiemens

0.04 (0.06)

0.12 (0.13)

0.020

Peaks/Sec, μsiemens

0.10 (0.08)

0.38 (0.44)

0.059

Basal Level, μsiemens

6.17 (2.71)

21.47 (13.22)

0.029

Mean of Peaks, μsiemens

0.10 (0.11)

0.32 (0.34)

0.435

Peaks/Sec, μsiemens

0.27 (0.17)

0.40 (0.19)

0.222

Basal Level, μsiemens

6.02 (2.75)

19.92 (14.09)

0.065

Mean of Peaks, μsiemens

0.04 (0.06)

0.26 (0.17)

0.048

Peaks/Sec, μsiemens

0.09 (0.10)

0.21 (0.20)

0.268

Basal Level, μsiemens

6.15 (2.89)

16.43 (13.66)

0.073

Infants’ Characteristics *

SC Measures †
Baseline (Pre-HLS)

Author Manuscript

Pain Phase (HLS)

Recovery Phase (Post-HLS)

HLS = Heel lance/squeeze,
*

Difference by Independent samples t test,

†
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Difference by Mann Whitney U test
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